000144568 001__ 144568
000144568 005__ 20240229133503.0
000144568 0247_ $$2doi$$a10.1097/SLA.0000000000003558
000144568 0247_ $$2pmid$$apmid:31425290
000144568 0247_ $$2ISSN$$a0003-4932
000144568 0247_ $$2ISSN$$a1528-1140
000144568 037__ $$aDKFZ-2019-02011
000144568 041__ $$aeng
000144568 082__ $$a610
000144568 1001_ $$0P:(DE-He78)448ff49e51672d79b4747339ac15c898$$aHuang, Lei$$b0$$eFirst author$$udkfz
000144568 245__ $$aSignificance of Examined Lymph Node Number in Accurate Staging and Long-term Survival in Resected Stage I-II Pancreatic Cancer-More is Better? A Large International Population-based Cohort Study.
000144568 260__ $$a[S.l.]$$bOvid38850$$c2021
000144568 3367_ $$2DRIVER$$aarticle
000144568 3367_ $$2DataCite$$aOutput Types/Journal article
000144568 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1685450092_28112
000144568 3367_ $$2BibTeX$$aARTICLE
000144568 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144568 3367_ $$00$$2EndNote$$aJournal Article
000144568 500__ $$a2021 Dec 1;274(6):e554-e563 / #EA:C070#LA:C070#
000144568 520__ $$aThis large international cohort study aimed to investigate the associations of examined lymph node (ELN) number with accurate staging and long-term survival in pancreatic adenocarcinoma (PaC) and to robustly determine the minimal and optimal ELN thresholds.ELN number is an important quality metric in cancer care. The recommended minimal ELN number in PaC to accurately stage cancer varies greatly across guidelines, and the optimal number especially to adequately stratify patient survival has not yet been established.Population-based data on patients with stage I to II PaC resected in 2003 to 2015 from the US Surveillance, Epidemiology, and End Results (SEER)-18 Program and Netherlands National Cancer Registry (NCR) were analyzed. Associations of ELN number with stage migration and survival were evaluated using multivariable-adjusted logistic and Cox regression models, respectively. The series of odds ratios (ORs) for negative-to-positive node stage migration and hazard ratios (HRs) for survival with more ELNs were fitted using a LOWESS smoother, and structural breakpoints were determined by Chow test.Overall 16,241 patients were analyzed. With increasing ELN number, both cohorts exhibited significant proportional increases from node-negative to node-positive disease [ORSEER-18=1.05, 95% confidence interval (CI) = 1.04-1.05; ORNCR = 1.10, 95% CI = 1.08-1.12] and serial improvements in survival (HRSEER-18 = 0.98, 95% CI = 0.98-0.99; HRNCR = 0.98, 95% CI = 0.97-0.99) per additional ELN after controlling for confounders. Associations for stage migration and survival remained significant in most stratifications by patient, tumor, and treatment factors. Cut-point analyses suggested a minimal threshold ELN number of 11 and an optimal number of 19, which were validated both internally in the derivative US cohort and externally in the Dutch cohort with the ability to well discriminate different probabilities of both survival and stage migration.In stage I to II PaC, more ELNs are associated with more precise nodal staging, which might largely explain the survival association. Our observational study does not suggest causality, and does not encourage more extended lymphadenectomy before further randomized evidence is obtained. Our results robustly conclude 11 ELNs as the minimal and suggest 19 ELNs as the optimal cut-points, for evaluating quality of lymph node examination and possibly for stratifying postoperative prognosis.
000144568 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000144568 588__ $$aDataset connected to CrossRef, PubMed,
000144568 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b1$$udkfz
000144568 7001_ $$0P:(DE-HGF)0$$aBalavarca, Yesilda$$b2
000144568 7001_ $$avan der Geest, Lydia$$b3
000144568 7001_ $$aLemmens, Valery$$b4
000144568 7001_ $$aGroot Koerkamp, Bas$$b5
000144568 7001_ $$avan Santvoort, Hjalmar C$$b6
000144568 7001_ $$aGrützmann, Robert$$b7
000144568 7001_ $$aBesselink, Marc G$$b8
000144568 7001_ $$0P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aSchrotz-King, Petra$$b9$$udkfz
000144568 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b10$$eLast author$$udkfz
000144568 773__ $$0PERI:(DE-600)2002200-1$$a10.1097/SLA.0000000000003558$$gp. 1 -$$n6$$pe554-e563$$tAnnals of surgery$$v274$$x0003-4932$$y2021
000144568 909CO $$ooai:inrepo02.dkfz.de:144568$$pVDB
000144568 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)448ff49e51672d79b4747339ac15c898$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000144568 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000144568 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000144568 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000144568 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000144568 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000144568 9132_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000144568 9141_ $$y2021
000144568 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz
000144568 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000144568 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144568 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144568 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000144568 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000144568 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANN SURG : 2017
000144568 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000144568 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000144568 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000144568 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000144568 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000144568 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000144568 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bANN SURG : 2017
000144568 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000144568 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000144568 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000144568 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000144568 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000144568 980__ $$ajournal
000144568 980__ $$aVDB
000144568 980__ $$aI:(DE-He78)C070-20160331
000144568 980__ $$aI:(DE-He78)C120-20160331
000144568 980__ $$aI:(DE-He78)HD01-20160331
000144568 980__ $$aUNRESTRICTED